ClarenceSAdooMD

Oncology • Avondale, AZ

Physician

Join to view full profile

Dr. Adoo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Adoo's full profile

Already have an account?

Office
10320 W McDowell Rd Bldg H #8025
Avondale, AZ 85392
Phone+1 623-238-7330
Is this information wrong?

Education & Training

University of MarylandFellowship, Hematology and Medical Oncology, 1995 - 1998
St Agnes HealthCareResidency, Internal Medicine, 1992 - 1995
University of Ghana Medical SchoolClass of 1990

Certifications & Licensure

AZ State Medical License 2002 - 2026
MD State Medical License 1994 - 2003
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2012

Clinical Trials

NBRST: Prospective Neo-adjuvant REGISTRY Trial Start of enrollment: 2011 Jul 01
Completed
Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer Start of enrollment: 2013 Mar 25
Completed
Phase 2
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL Start of enrollment: 2014 Jun 01
Terminated
Phase 2
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) Start of enrollment: 2015 May 01
Completed
Phase 3
Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer Start of enrollment: 2017 Feb 22
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

9 citations
An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer.
Jeffrey L. Vacirca, Arlene Chan, Klára Mezei, Clarence S. Adoo, Zsuzsanna Pápai
Cancer Medicine. 2018-05-01

Hospital Affiliations

HonorHealth John C. Lincoln Medical CenterPhoenix, Arizona
Abrazo Arrowhead CampusGlendale, Arizona
Banner Boswell Medical CenterSun City, Arizona
Banner Del E. Webb Medical CenterSun City West, Arizona
Banner Estrella Medical CenterPhoenix, Arizona
Banner Thunderbird Medical CenterGlendale, Arizona
HonorHealth Deer Valley Medical CenterPhoenix, Arizona
Banner - University Medical Center PhoenixPhoenix, Arizona